Physician profile
John Hall
NPI 1568451201
$5,145.33
in general payments reported to CMS, 2019-2025
29 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,883 · 2020: $141 · 2021: $832 · 2022: $364 · 2023: $358 · 2024: $233 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,173.49 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $994.77 | 2019-2023 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $517.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $296.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.06 | 2019-2023 | Jardiance |
| Radius Health, INC. | $198.08 | 2019-2020 | |
| Globus Medical, INC. | $174.82 | 2025 | Creo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.36 | 2019 | |
| Inspire Medical Systems, INC. | $145.67 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $144.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $142.92 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $140.23 | 2019-2024 | Trelegy Ellipta |
| Genzyme Corporation | $124.14 | 2024 | |
| Merck Sharp & Dohme LLC | $114.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.06 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $72.81 | 2019 | |
| Lilly USA, LLC | $63.61 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $63.26 | 2021 | |
| Astellas Pharma US INC | $57.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.61 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $41.53 | 2019 | |
| Abbvie INC. | $34.63 | 2019 | |
| Corcept Therapeutics | $33.98 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $28.40 | 2019 | |
| Allergan, INC. | $28.35 | 2019 | |
| Dexcom, INC. | $21.29 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $16.03 | 2021 | |
| Exact Sciences Corporation | $14.95 | 2023 | Cologuard Collection Kit |
| Antares Pharma, INC. | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.